Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

iwCLL 2019 | Is MRD ready for clinical practice?

Lydia Scarfò • 31 Oct 2019
iwCLL 2019
Chronic Lymphocytic Leukemia Leukemia

Lydia Scarfò, MD, Vita-Salute San Raffaele University, Milan, Italy shares her opinion on measurable residual disease (MRD) and how we might be able to integrate this intermediate endpoint into clinical practice. This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.

More from Lydia Scarfò

From fixed-duration regimens to novel agents: current & future perspectives on CLL treatment 2:34
From fixed-duration regimens to novel agents: current & future perspectives on CLL treatment
Lydia Scarfò • 4 Sep 2025
MRD assessment in CLL: importance of standardizing tests & potential clinical application 3:04
MRD assessment in CLL: importance of standardizing tests & potential clinical application
Lydia Scarfò • 4 Sep 2025
Tailoring therapy for younger, fit patients with CLL: advice for community oncologists 2:17
Tailoring therapy for younger, fit patients with CLL: advice for community oncologists
Lydia Scarfò • 5 Sep 2025
The importance of integrating genetic profiling in CLL: from NGS to emerging biomarkers 1:39
The importance of integrating genetic profiling in CLL: from NGS to emerging biomarkers
Lydia Scarfò • 4 Sep 2025

Related Videos

The value and mission of the International Workshop on Acute Leukemias 14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddock et al. • 21 Oct 2025
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years? 1:30
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years?
Koichi Takahashi • 26 Sep 2025
One big question with Naval Daver: what AML advance could transform frontline care in three years? 1:05
One big question with Naval Daver: what AML advance could transform frontline care in three years?
Naval Daver • 26 Sep 2025
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years? 3:13
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years?
Charles Craddock • 26 Sep 2025
The content of VJHemOnc is intended for healthcare professionals